Causes of Hospitalizations in Pediatric Patients with Thalassemia under the National Health Coverage Scheme in Thailand
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Higgs, D.R.; Thein, S.L.; Wood, W.G. Thalassaemia: Classification, genetics and relationship to other inherited disorders of haemoglobin. In The Thalassaemia Syndromes; Weatherall, D.J., Clegg, J.B., Eds.; Blackwell Science: Oxford, UK, 2001; pp. 121–132. [Google Scholar]
- Fucharoen, S.; Weatherall, D.J. Progress Toward the Control and Management of the Thalassemias. Hematol. Oncol. Clin. N. Am. 2016, 30, 359–371. [Google Scholar] [CrossRef] [PubMed]
- Anurathapan, U.; Pakakasama, S.; Mekjaruskul, P.; Sirachainan, N.; Songdej, D.; Chuansumrit, A.; Charoenkwan, P.; Jetsrisuparb, A.; Sanpakit, K.; Pongtanakul, B.; et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol. Blood Marrow Transplant. 2014, 20, 2066–2071. [Google Scholar] [CrossRef] [PubMed]
- Thompson, A.A.; Walters, M.C.; Kwiatkowski, J.; Rasko, J.E.J.; Ribeil, J.A.; Hongeng, S.; Magrin, E.; Schiller, G.J.; Payen, E.; Semeraro, M.; et al. Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N. Engl. J. Med. 2018, 378, 1479–1493. [Google Scholar] [CrossRef] [PubMed]
- Frangoul, H.; Altshuler, D.; Cappellini, M.D.; Chen, Y.S.; Domm, J.; Eustace, B.K.; Foell, J.; de la Fuente, J.; Grupp, S.; Handgretinger, R.; et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N. Engl. J. Med. 2021, 384, 252–260. [Google Scholar] [CrossRef] [PubMed]
- Locatelli, F.; Thompson, A.A.; Kwiatkowski, J.L.; Porter, J.B.; Thrasher, A.J.; Hongeng, S.; Sauer, M.G.; Thuret, I.; Lal, A.; Algeri, M.; et al. Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia. N. Engl. J. Med. 2022, 386, 415–427. [Google Scholar] [CrossRef] [PubMed]
- Viprakasit, V.; Ekwattanakit, S. Clinical Classification, Screening and Diagnosis for Thalassemia. Hematol. Oncol. Clin. N. Am. 2018, 32, 193–211. [Google Scholar] [CrossRef] [PubMed]
- Ho, W.L.; Lin, K.H.; Wang, J.D.; Hwang, J.S.; Chung, C.W.; Lin, D.T.; Jou, S.T.; Lu, M.Y.; Chern, J.P. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant. 2006, 37, 569–574. [Google Scholar] [CrossRef] [PubMed]
- Riewpaiboon, A.; Nuchprayoon, I.; Torcharus, K.; Indaratna, K.; Thavorncharoensap, M.; Ubol, B.O. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res. Notes 2010, 3, 29. [Google Scholar] [CrossRef] [PubMed]
- Moirangthem, A.; Phadke, S.R. Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia. Indian J. Pediatr. 2018, 85, 102–107. [Google Scholar] [CrossRef] [PubMed]
- Reed-Embleton, H.; Arambepola, S.; Dixon, S.; Maldonado, B.N.; Premawardhena, A.; Arambepola, M.; Khan, J.A.M.; Allen, S. A cost-of-illness analysis of beta-Thalassaemia major in children in Sri Lanka—Experience from a tertiary level teaching hospital. BMC Pediatr. 2020, 20, 257. [Google Scholar] [CrossRef] [PubMed]
- Uchil, A.; Muranjan, M.; Gogtay, N.J. Economic burden of beta-thalassaemia major receiving hypertransfusion therapy at a public hospital in Mumbai. Natl. Med. J. India 2023, 36, 11–16. [Google Scholar] [CrossRef] [PubMed]
- Esmaeilzadeh, F.; Ahmadi, B.; Vahedi, S.; Barzegari, S.; Rajabi, A. Major Thalassemia, Screening or Treatment: An Economic Evaluation Study in Iran. Int. J. Health Policy Manag. 2022, 11, 1112–1119. [Google Scholar] [CrossRef] [PubMed]
- Eleftheriou, A.; Antoniou, E.; Darba, J.; Ascanio, M.; Angastiniotis, M.; Farmakis, D. Estimating the Cost of Thalassemia Care across the World: A Thalassemia International Federation Model. Hemoglobin 2022, 46, 308–311. [Google Scholar] [CrossRef] [PubMed]
- Udeze, C.; Evans, K.A.; Yang, Y.; Lillehaugen, T.; Manjelievskaia, J.; Mujumdar, U.; Li, N.; Andemariam, B. Economic and clinical burden of managing transfusion-dependent beta-thalassemia in the United States. J. Med. Econ. 2023, 26, 924–932. [Google Scholar] [CrossRef] [PubMed]
- Chuncharunee, S.; Teawtrakul, N.; Siritanaratkul, N.; Chueamuangphan, N. Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand. PLoS ONE 2019, 14, e0214148. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th ed.; World Health Organization: Geneva, Switzerland, 2010; Available online: https://icd.who.int/browse10/2010/en#/ (accessed on 1 January 2022).
- Teawtrakul, N.; Chansung, K.; Sirijerachai, C.; Wanitpongpun, C.; Thepsuthammarat, K. The impact and disease burden of thalassemia in Thailand: A population-based study in 2010. J. Med. Assoc. Thai. 2012, 95 (Suppl. 7), S211–S216. [Google Scholar] [PubMed]
- Bazrgar, M.; Peiravian, F.; Abedpour, F.; Karimi, M. Causes for hospitalization and death in Iranian patients with beta-thalassemia major. Pediatr. Hematol. Oncol. 2011, 28, 134–139. [Google Scholar] [CrossRef] [PubMed]
- Origa, R.; Anni, F.; Mereu, L.; Follesa, I.; Campus, S.; Dessi, C.; Foschini, M.L.; Leoni, G.; Moi, P.; Morittu, M.; et al. Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015. Ann. Hematol. 2017, 96, 1041–1042. [Google Scholar] [CrossRef] [PubMed]
- Saliba, A.N.; Moukhadder, H.M.; Harb, A.; Beydoun, H.; Bou-Fakhredin, R.; Taher, A.T. Causes of hospital admission in beta-thalassemia (CHAT) in Lebanon from 1995 to 2015: A pilot retrospective study from a tertiary care center. Am. J. Hematol. 2017, 92, E652–E653. [Google Scholar] [CrossRef] [PubMed]
- Bank of Thailand Daily Foreign Exchange Rates. Available online: https://www.bot.or.th/en/statistics/exchange-rate.html (accessed on 8 December 2023).
- Tongsong, T.; Charoenkwan, P.; Sirivatanapa, P.; Wanapirak, C.; Piyamongkol, W.; Sirichotiyakul, S.; Srisupundit, K.; Tongprasert, F.; Luewan, S.; Ratanasiri, T.; et al. Effectiveness of the model for prenatal control of severe thalassemia. Prenat. Diagn. 2013, 33, 477–483. [Google Scholar] [CrossRef] [PubMed]
Fiscal Year | ||||||
---|---|---|---|---|---|---|
Diagnosis by ICD10 * | 2015 | 2016 | 2017 | 2018 | 2019 | Total |
D560 Alpha-thalassemia | 5739 | 6991 | 8479 | 9420 | 11,472 | 42,101 |
D561 Beta-thalassemia | 34,677 | 37,875 | 42,722 | 44,528 | 46,907 | 206,709 |
D568 Other thalassemias | 314 | 465 | 360 | 382 | 325 | 1846 |
D569 Thalassemia, unspecified | 18,092 | 18,883 | 17,538 | 15,357 | 15,891 | 85,761 |
Total diagnosis | 58,822 | 64,214 | 69,099 | 69,687 | 74,595 | 336,417 |
Total admissions | 58,753 | 64,144 | 69,021 | 69,599 | 74,537 | 336,054 |
Total (person) | 15,055 | 16,403 | 15,909 | 15,425 | 15,798 | 41,237 |
Total NHC admission | 1,743,869 | 1,857,172 | 1,764,712 | 1,838,505 | 1,788,952 | 8,993,210 |
Number of population | 14,128,228 | 13,904,284 | 13,730,927 | 13,529,812 | 13,339,906 | - |
Rate/100 admissions | 3.37 | 3.45 | 3.91 | 3.79 | 4.17 | 3.74 |
Rate/100,000 population | 416 | 461 | 503 | 514 | 559 | - |
Age | ||||||
---|---|---|---|---|---|---|
Diagnosis by ICD10 * | 0–1 y | 1–6 y | 6–11 y | 11–16 y | 16–18 y | Total |
D560 Alpha-thalassemia | 86 | 681 | 13,294 | 22,246 | 5794 | 42,101 |
D561 Beta-thalassemia | 78 | 1218 | 48,638 | 109,162 | 47,613 | 206,709 |
D568 Other thalassemias | 3 | 48 | 568 | 859 | 368 | 1846 |
D569 Thalassemia, unspecified | 89 | 2539 | 25,589 | 36,453 | 21,091 | 85,761 |
Total diagnosis | 256 | 4486 | 88,089 | 168,720 | 74,866 | 336,417 |
Total admissions | 256 | 4484 | 87,992 | 168,530 | 74,792 | 336,054 |
Total (person) | 246 | 2881 | 16,930 | 16,703 | 12,059 | 41,237 |
Total NHC admission | 2,899,951 | 782,382 | 2,626,135 | 1,480,226 | 1,204,516 | 8,993,210 |
Rate/100 admissions | 0.01 | 0.57 | 3.35 | 11.39 | 6.21 | 3.74 |
Fiscal Year | ||||||
---|---|---|---|---|---|---|
Co-Diagnoses | 2015 | 2016 | 2017 | 2018 | 2019 | Total |
Infections | 8423 | 10,078 | 9555 | 8846 | 8736 | 45,638 |
-Respiratory infections | 5468 | 6999 | 6791 | 5967 | 5380 | 30,605 |
-Intestinal infectious diseases | 1444 | 1714 | 1607 | 1617 | 1520 | 7902 |
-Arthropod-borne | 762 | 615 | 412 | 618 | 1055 | 3462 |
-Other infections | 1326 | 1445 | 1327 | 1181 | 1350 | 6629 |
Heart failure/Arrhythmias | 174 | 172 | 127 | 110 | 101 | 684 |
Other cardiovascular diseases | 364 | 459 | 360 | 338 | 318 | 1839 |
Cholelithiasis/Cholecystitis | 183 | 196 | 210 | 202 | 242 | 1033 |
Diabetes mellitus | 51 | 38 | 38 | 24 | 21 | 172 |
Blood transfusion | 124 | 164 | 146 | 175 | 199 | 808 |
Hemochromatosis | 13,641 | 16,704 | 21,614 | 23,473 | 25,530 | 100,962 |
Other | 10,962 | 11,345 | 11,623 | 10,809 | 11,109 | 55,848 |
Total co-diagnosis | 34,499 | 39,851 | 44,255 | 44,514 | 46,825 | 209,944 |
Total admissions | 58,753 | 64,144 | 69,021 | 69,599 | 74,537 | 336,054 |
Age | ||||||
---|---|---|---|---|---|---|
Co-Diagnoses | 0–1 y | 1–6 y | 6–11 y | 11–16 y | 16–18 y | Total |
Infections | 16 | 2179 | 19,548 | 16,798 | 7097 | 45,638 |
-Respiratory infections | 11 | 1352 | 14,531 | 11,154 | 3557 | 30,605 |
-Intestinal infections | 2 | 841 | 3631 | 2331 | 1097 | 7902 |
-Arthropod-borne | - | 24 | 508 | 1800 | 1130 | 3462 |
-Other infections | 4 | 397 | 2228 | 2325 | 1675 | 6629 |
Heart failure/Arrhythmias | 3 | 13 | 126 | 221 | 321 | 684 |
Other cardiovascular diseases | 5 | 33 | 279 | 755 | 767 | 1839 |
Cholelithiasis/Cholecystitis | - | - | 20 | 383 | 630 | 1033 |
Diabetes mellitus | 1 | 1 | 8 | 19 | 143 | 172 |
Blood transfusion | - | 16 | 286 | 324 | 182 | 808 |
Hemochromatosis | 2 | 36 | 16,983 | 59,120 | 24,821 | 100,962 |
Other | 230 | 1403 | 14,779 | 23,919 | 15,517 | 55,848 |
Total co-diagnosis | 258 | 4116 | 53,379 | 102,351 | 49,840 | 209,944 |
Total admissions | 256 | 4484 | 87,992 | 168,530 | 74,792 | 336,054 |
Fiscal Year | ||||||
---|---|---|---|---|---|---|
Cost of Hospital Admission | 2015 | 2016 | 2017 | 2018 | 2019 | Total |
Total cost of hospital admission (×1 million baht) | 281.8 | 309.3 | 338.8 | 340.2 | 375.1 | 1645.1 |
Total cost of hospital admission for iron chelation (×1 million baht) (% of total cost) | 79.2 (28.1) | 98.9 (32.0) | 124.8 (36.8) | 144.8 (42.6) | 161.5 (43.1) | 609.2 (37.0) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Charoenkwan, P.; Komvilaisak, P.; Thepsuthummarat, K.; Seksarn, P.; Torcharus, K. Causes of Hospitalizations in Pediatric Patients with Thalassemia under the National Health Coverage Scheme in Thailand. Thalass. Rep. 2024, 14, 10-17. https://doi.org/10.3390/thalassrep14010002
Charoenkwan P, Komvilaisak P, Thepsuthummarat K, Seksarn P, Torcharus K. Causes of Hospitalizations in Pediatric Patients with Thalassemia under the National Health Coverage Scheme in Thailand. Thalassemia Reports. 2024; 14(1):10-17. https://doi.org/10.3390/thalassrep14010002
Chicago/Turabian StyleCharoenkwan, Pimlak, Patcharee Komvilaisak, Kaewjai Thepsuthummarat, Panya Seksarn, and Kitti Torcharus. 2024. "Causes of Hospitalizations in Pediatric Patients with Thalassemia under the National Health Coverage Scheme in Thailand" Thalassemia Reports 14, no. 1: 10-17. https://doi.org/10.3390/thalassrep14010002